Synektik (FRA:A2P) Total Equity: €36.7 Mil (As of Mar. 2026)


FRA:A2P Synektik SA FRA:A2P
60 GF Score
Price €83.70
GF Value €52.48
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Synektik Total Equity?

Synektik FRA:A2P +4.17% 60 Total Equity is €36.7 Mil as of Mar. 2026. GuruFocus rates FRA:A2P with a GF Score™ of 60/100 and a GF Value™ of €52.48 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Synektik's total equity for the quarter that ended in Mar. 2026 was €36.7 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Synektik Total Equity Historical Data

* Premium members only.

The historical data trend for Synektik's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synektik Total Equity Chart

Synektik Annual Data
Trend Dec14 Dec15 Dec16 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.58 18.64 20.32 31.05 43.96

Synektik Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.65 44.24 51.71 59.76 36.71
FRA:A2P
60GF Score
Synektik SA FRA:A2P
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synektik Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Synektik's Total Equity for the fiscal year that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=86.812-42.852
=44.0

Synektik's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=112.949-76.242
=36.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €36.7 Mil mean?
Synektik (FRA:A2P) has a Total Equity of €36.7 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Synektik and its competitors.
Is Synektik's Total Equity too high?
Synektik's current Total Equity is €36.7 Mil. Overall, Synektik has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's Total Equity compare to ABT and SYK?
Synektik's Total Equity of €36.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Synektik and its competitors. Synektik's current Total Equity is €36.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (FRA:A2P) is currently considered Significantly Overvalued. The stock's GF Value™ is €52.48, compared to a current price of €83.70 — trading 59.5% above its estimated fair value. The current Total Equity is €36.7 Mil. Synektik's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Synektik (FRA:A2P), the current Total Equity is €36.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synektik (FRA:A2P) Overvalued in 2026?

Based on GuruFocus' analysis, Synektik stock appears to be overvalued. The current stock price of €83.70 is trading 59.5% above its estimated GF Value™ of €52.48. GuruFocus considers Synektik to be Significantly Overvalued.

Key valuation signals for FRA:A2P:

  • Total Equity: €36.7 Mil
  • GF Value™: €52.48 vs. price of €83.70 (59.5% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the FRA:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synektik Business Description

Other Exchanges SNT:Poland
Address Aleja Wincentego Witosa 31, Warsaw, POL, 00-710
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
60GF Score

Get the complete analysis for FRA:A2P

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€83.70
Price
€52.48
GF Value